Akums Drugs and Pharmaceuticals Limited unveiled its Tamsulosin + Tadalafil Capsule therapy to the Indian market. This groundbreaking combined therapy, encapsulated in a hard gelatin capsule at a fixed dose, represents a noteworthy achievement for the company, according to a press release.
Remarkably, Akums has secured approval from the Drug Controller General of India (DCGI) as the first Contract Development and Manufacturing Organization (CDMO) for the unique formulation of Tamsulosin 0.4/0.4mg + Tadalafil 2.5/5mg.
The company stated, “Tamsulosin is a selective alpha1A-adrenergic receptor antagonist. The effects of tamsulosin are targeted for the smooth muscle receptors of the prostate and urethra. Blocking this receptor relaxes the smooth muscle of the bladder and urethra to improve urine flow. It is primarily used when an enlarged prostate impedes normal urine flow and bladder emptying.”
In parallel, Tadalafil’s mechanism of action focuses on inhibiting PDE5, a vital enzyme situated in the vascular smooth muscle cells of the corpus cavernosum. By impeding cGMP hydrolysis, Tadalafil encourages cGMP accumulation and the relaxation of vascular smooth muscle, facilitating the development of a physiologically-induced erection, contingent upon sexual stimulation, it further explained.
Sanjeev Jain, Jt. Managing Director of Akums Drugs & Pharmaceuticals Ltd., stated, “The introduction of the Tamsulosin + Tadalafil Capsule underscores Akums’ commitment to advancing healthcare solutions for patients grappling with benign prostatic hyperplasia and erectile dysfunction. This innovative combination therapy not only offers a more convenient treatment option but also represents a significant leap forward in our pursuit of enhancing patient outcomes.”
Each hard gelatin capsule is composed of Tamsulosin Hydrochloride IP at 0.4/0.4mg (in its Extended-Release Form) and Tadalafil IP at 2.5/5mg (as a Film Coated Tablet).
With a focus on the urology segment, the Tamsulosin + Tadalafil Capsule showcases several key features. It reportedly delivers substantial improvements in BPH (Benign Prostatic Hyperplasia) and Erectile Dysfunction Index, significantly enhancing Total, Voiding, and Storage IPSS (International Prostate Symptom Score). Consequently, it offers enhanced efficacy for the relief of Lower Urinary Tract Symptoms (LUTS).
